Literature DB >> 1643696

Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro.

M A Kolber1, P Hill.   

Abstract

The cytochalasins are fungal metabolites that have previously been shown to have some chemotherapeutic potential. When various cell types are treated in vitro with both cytochalasin B and vincristine, the resultant DNA fragmentation is greater than the sum of that caused by each agent alone. The levels necessary to achieve this potentiation are obtainable in vivo. DNA fragmentation induced by cytochalasin E, an actin-specific agent, is potentiated by vincristine. Pretreatment of the mastocytoma line P815 with vincristine results in an enhancement of the ability of cytochalasin B to fragment DNA. These results indicate that cytochalasin B might be effective as a chemotherapeutic agent in the presence of vincristine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643696     DOI: 10.1007/bf00686297

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Uptake and binding of vincristine by murine leukemia cells.

Authors:  W A Bleyer; S A Frisby; V T Oliverio
Journal:  Biochem Pharmacol       Date:  1975-03-01       Impact factor: 5.858

2.  The pharmacokinetics of [3H]-vincristine in man.

Authors:  R A Bender; M C Castle; D A Margileth; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

3.  Human cytotoxic T lymphocytes and activated peripheral blood lymphocytes enhance cytochalasin B-induced DNA fragmentation of indicator bystander cells.

Authors:  M A Kolber
Journal:  Cell Immunol       Date:  1992-01       Impact factor: 4.868

4.  Antitumor activity of cytochalasin D.

Authors:  K Katagiri; S Matsuura
Journal:  J Antibiot (Tokyo)       Date:  1971-10       Impact factor: 2.649

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Mechanism of action of cytochalasin B on actin.

Authors:  S MacLean-Fletcher; T D Pollard
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

7.  Effects of cytochalasins on mammalian cells.

Authors:  S B Carter
Journal:  Nature       Date:  1967-01-21       Impact factor: 49.962

8.  In vitro combination chemotherapy demonstrating potentiation of vincristine cytotoxicity by prednisolone.

Authors:  F Rosner; Y Hirshaut; H W Grünwald; M Dietrich
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

9.  Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma.

Authors:  P F Bousquet; L A Paulsen; C Fondy; K M Lipski; K J Loucy; T P Fondy
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

10.  Cytochalasin B: preparation, analysis in tissue extracts, and pharmacokinetics after intraperitoneal bolus administration in mice.

Authors:  K M Lipski; J D McQuiggan; K J Loucy; T P Fondy
Journal:  Anal Biochem       Date:  1987-03       Impact factor: 3.365

View more
  9 in total

Review 1.  Optimizing management in autoimmune hepatitis with liver failure at initial presentation.

Authors:  Jonathan R Potts; Sumita Verma
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

2.  Progress in the Chemistry of Cytochalasans.

Authors:  Hucheng Zhu; Chunmei Chen; Qingyi Tong; Yuan Zhou; Ying Ye; Lianghu Gu; Yonghui Zhang
Journal:  Prog Chem Org Nat Prod       Date:  2021

Review 3.  Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.

Authors:  Kalpana Tilekar; Neha Upadhyay; Cristina V Iancu; Vadim Pokrovsky; Jun-Yong Choe; C S Ramaa
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-21       Impact factor: 10.680

4.  Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.

Authors:  Matthew Trendowski; Joan M Mitchell; Christine M Corsette; Christopher Acquafondata; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-01-07       Impact factor: 3.850

5.  Using cytochalasins to improve current chemotherapeutic approaches.

Authors:  Matthew Trendowski
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

6.  Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B.

Authors:  Matthew Trendowski; Joseph N Zoino; Timothy D Christen; Christopher Acquafondata; Thomas P Fondy
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

7.  Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.

Authors:  Matthew Trendowski; Timothy D Christen; Christopher Acquafondata; Thomas P Fondy
Journal:  BMC Cancer       Date:  2015-09-10       Impact factor: 4.430

Review 8.  Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers.

Authors:  Matthew Trendowski
Journal:  Chemother Res Pract       Date:  2015-08-25

Review 9.  Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.

Authors:  Aneta Gandalovičová; Daniel Rosel; Michael Fernandes; Pavel Veselý; Petr Heneberg; Vladimír Čermák; Luboš Petruželka; Sunil Kumar; Victoria Sanz-Moreno; Jan Brábek
Journal:  Trends Cancer       Date:  2017-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.